3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
4
Recurrence
3
Myeloproliferative Disorders
3
Lymphoma
3
Primary Myelofibrosis
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
43
venetoclax
30
Cytarabine
25
fludarabine
22
fludarabine phosphate
17
Azacitidine
16
Mycophenolic Acid
13
Whole-Body Irradiation
12
Dexamethasone
12
ruxolitinib
11
Rituximab
11
Busulfan
11
Vincristine
10
Methotrexate
10
Etoposide
10
Tacrolimus
9
Daunorubicin
9
Mercaptopurine
8
Filgrastim
8
Dasatinib
8
ibrutinib
7
Prednisone
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Granulocyte Colony-Stimulating Factor
7
Doxorubicin
7
Decitabine
7
pegaspargase
6
blinatumomab
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
parsaclisib
×
1 year
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts